Mazdutide quick reference
What is Mazdutide?
Weekly injection that hits GLP-1 and glucagon receptors.
Used for weight loss and blood sugar control.
Approved in China (2025). No US or EU approval found.
How Mazdutide works
Lowers appetite and helps insulin release.
Adds an energy-use and liver pathway.
Doses rise over weeks to ease stomach effects.
What Mazdutide is studied for
Lost 11% and 14% in 48 weeks (China).
Lost 16.7% in 60 weeks (China).
10 and 16 mg gave 15.6% and 18.1% loss by week 32.
Beat dulaglutide on HbA1c and weight at 28 weeks.
Mazdutide dosing protocol
| Weeks (GLORY-1) | Weekly amount |
|---|---|
| 1-4 | 2 mg (both groups) |
| 5-8 | 4 mg (both groups) |
| 9-48 | 4 mg group stays on 4 mg; 6 mg group goes up to 6 mg |
| GLORY-2 (60 weeks) | 9 mg target; the step-up plan was not in the sources I checked |
GLORY-1 schedule is from the ClinicalTrials.gov entry NCT05607680. The 4 mg group was 2 mg for 4 weeks, then 4 mg for 44 weeks. The 6 mg group was 2 mg, 4 mg, then 6 mg for 40 weeks. This is a trial schedule. The Chinese label was not read, so check it for the exact approved doses.
Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.
Mixing
Common example. Add BAC water slowly, swirl, keep cold.
What the research found
GLORY-1: 610 adults in China with overweight or obesity, 48 weeks. GLORY-2: 461 adults with obesity, 60 weeks. Average body weight change (treatment-policy analysis):
Ji L et al. N Engl J Med 2025 (GLORY-1, NCT05607680). JAMA 2026 (GLORY-2, NCT06164873). Both trials were in Chinese adults, so results may differ elsewhere.
Mazdutide community experience
What users report. Not tested in trials.
Positive reports
- Appetite drop GLP-1 action makes less hunger the main report.
- Different feel Users compare the glucagon arm with tirzepatide.
- Easy to track Weight, waist and intake are simple to follow.
Negative & mixed
- Stomach upset Nausea and diarrhea cloud early weight changes.
- Unverified vials Reports cannot confirm trial-grade material.
- Shaky rankings Different trials make head-to-head claims unreliable.
Mazdutide stacking
Retatrutide adds GIP. Not studied together.
Both already strong. Not studied together.
Mazdutide side effects & safety
Common
- Vomiting: 53% on 9 mg, 1% placebo.
- Nausea: 47% on 9 mg, 3% placebo.
- Diarrhea: 39% on 9 mg, 6% placebo.
- Most events mild to moderate.
- Less appetite can make eating enough harder.
Less common
- Quit for side effects: 2.9% on 9 mg.
- Up to 20% quit on 16 mg in US phase 2.
- Long-term outcomes are not yet known.
Precautions
- Pregnancy or breastfeeding: ask a doctor first.
- Insulin or sulfonylureas: sugar can drop; doses may need change.
- Persistent vomiting or diarrhea can cause dehydration.
- Severe belly pain needs urgent care.
Our verdict on Mazdutide
Real phase 3 weight-loss data and a China approval. Stomach effects are the main cost.
Mazdutide FAQ
Is mazdutide approved?
In China since 2025, for weight management. Not in the US or EU.
How much weight loss?
11% on 4 mg and 14% on 6 mg at 48 weeks.
How is it different from tirzepatide?
It adds glucagon, not GIP, to GLP-1.
Sources
- Ji L et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med 2025 (GLORY-1), NCT05607680
- Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity (GLORY-2). JAMA 2026, NCT06164873
- ClinicalTrials.gov NCT05607680 (arm schedule)
- Innovent press release via PR Newswire / PharmaFocus Asia, 30 June 2025 (NMPA approval for chronic weight management in adults with BMI 28+ or 24+ with a related condition)
- Efficacy and safety of mazdutide in adults with obesity or overweight: US phase 2 trial. Lancet Diabetes Endocrinol 2026, NCT06124807 (PubMed 42628555)
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature 2026 (PubMed 41407860)